Search | Clinical Trials Finder

Conditions: Secondary Immune Deficiency
Interventions: IgPro20; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more

Conditions: Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinaemia, Hyper-IgM Syndrome
Interventions: Gammaplex (5%), Gammaplex 10; Biological
Lead sponsor: Bio Products Laboratory; Other
Eligibility: 2 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 14
States / cities: Chandler, Arizona • Long Beach, California • Los Angeles, California + 10 more

Conditions: Child Nutrition Disorders
Interventions: nutrition and hygiene education; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 1 Month to 6 Months
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: HIV Infections
Interventions: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 51 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Interventions: Panzyga, Placebo; Biological · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: St. Petersburg, Florida • Columbus, Georgia • Macon, Georgia + 10 more

Conditions: Mevalonic Aciduria, Mevalonate Kinase Deficiency, Immune System Diseases, Periodic Fever Syndromes, Hereditary, Lipid Metabolism, Inborn Errors
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetic Nephropathy, Proteinuria, Oxidative Stress
Interventions: N-acetylcysteine placebo and silibin placebo, N-acetylcysteine active and silibin placebo, N-acetylcysteine placebo and silibin active, N-acetylcysteine active and silibin active, N-acetylcysteine active + high-dose silibin active; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 76 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cholesterol, HDL, Lipid Metabolism, Inborn Errors, Tangier Disease, LCAT Deficiency, Cholesteryl Ester Transfer Protein (CETP) Deficiency
Interventions: 3H-cholesterol bound to albumin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hematologic Disorder
Interventions: Lenalidomide, Influenza Vaccine, Pneumovax Vaccine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, Pregnancy
Interventions: CD4-IgG; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Brooklyn, New York • Houston, Texas

Conditions: Urea Cycle Disorder, Organic Acidemia, Maple Syrup Urine Disease, Glutaric Acidemia I, Fatty Acid Oxidation Disorder, Hypoxic-Ischemic Encephalopathy
Interventions: Not listed
Lead sponsor: Children's National Research Institute; Other
Eligibility: 7 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 3
States / cities: Birmingham, Alabama • St Louis, Missouri • Rochester, New York

Conditions: HIV Infections, HIV Seronegativity
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Placebo version of rgp120/HIV-1MN, Placebo version of rgp120/HIV-1SF2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 3 Days
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 36
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 23 more

Conditions: Weight Loss, Muscle Loss, Bone Loss
Interventions: Dietary Protein Intake; Other
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years to 42 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Factor VIII Deficiency, Congenital
Interventions: Emicizumab; Drug
Lead sponsor: Indiana Hemophilia &Thrombosis Center, Inc.; Other
Eligibility: 5 Years to 45 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 110 Years
Enrollment: 999,999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2099
U.S. locations: 42
States / cities: Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more

Conditions: HIV Infections
Interventions: MF59, rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1998
U.S. locations: 4
States / cities: Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 1 more

Conditions: Primary Immune Deficiencies, Autoimmune Diseases, Inflammatory Diseases, Common Variable Immune Deficiencies, Hypogammaglobulinemia
Interventions: Not listed
Lead sponsor: O & O Alpan LLC; Other
Eligibility: 1 Day and older
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Growth Hormone Deficiency
Interventions: growth hormone (Nutropin); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 17 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, chromatography, high performance liquid chromatography, immunoenzyme technique; Genetic · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1975 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infections
Interventions: gp160 Vaccine (Immuno-AG), rgp120/HIV-1IIIB, rgp120/HIV-1MN, rgp120/HIV-1 SF-2, HIVAC-1e; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1994
U.S. locations: 2
States / cities: Rochester, New York • Seattle, Washington

Conditions: HIV Infections
Interventions: CD4-IgG, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Worcester, Massachusetts

Conditions: Quad Atrophy
Interventions: Amino Acid, Placebo; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 40 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: EP HIV-1043, EP HIV-1090; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Rochester, New York

Search by objective public record fields.

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases

A Nutrition/Hygiene Education Program for the Prevention of Child Malnutrition in Rural Kenya

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

Mendelian Reverse Cholesterol Transport Study

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns

Systemic Biomarkers of Brain Injury From Hyperammonemia

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency

Hemlibra in Mild Hemophilia A

Integrated Cancer Repository for Cancer Research

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

Investigation of Immune Disorders and Deficiencies

304-C03/L3301n: Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

Trial of Essential Amino Acid Supplementation in Protein Deficient Patients Following Total Knee Arthroplasty

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults